Law360, New York (July 25, 2011, 6:18 PM ET) -- Lupin Ltd. said Monday it had reached a deal with Medicis Pharmaceutical Corp. to make a generic version of the acne drug Solodyn and to start a development collaboration worth an initial $20 million, resolving patent litigation in Maryland federal court.
The agreement allows Mumbai-based Lupin to sell a generic version of Solodyn in three different doses as early as November, according to the company. In a separate agreement, Lupin said it would join forces with Medicis to use its proprietary formulation technology to develop new...
Lupin, Medicis Reach Deal Over Generic Solodyn
To view the full article, take a free trial now.
